Clinical Trials

45 enrolled 12 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01258933 2025-10-01

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

4 enrolled 7 charts

Phase 2 Active not recruiting

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01361711 2025-05-23

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

53 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01437709 2025-02-28

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

30 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT01243190 2024-09-19

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

44 enrolled 7 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03488225 2024-07-16

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

4 enrolled 11 charts

Burkitt Lymphoma

NCT02199184 2024-06-11

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

14 enrolled 10 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01527149 2024-02-07

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

37 enrolled 19 charts

Lymphoma, Mantle-Cell

NCT01145209 2023-11-28

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

32 enrolled 16 charts

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04189588 2023-10-06

versus

34 enrolled 11 charts

Oncology Patients Receiving Chemotherapy

NCT01060384 2023-10-04

Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1/2 Completed

46 enrolled 8 charts

319 enrolled 18 charts 1 FDA

Lymphoma, Non-Hodgkin

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Phase 3 Completed

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02049515 2023-09-21

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Phase 3 Completed

99 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01190449 2021-08-18

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

51 enrolled 7 charts

Lymphoma, Lymphoma, Follicular

NCT01444716 2021-07-26

Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia

34 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01363128 2021-05-03

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

72 enrolled 10 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01497496 2021-04-27

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

29 enrolled 9 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Completed

241 enrolled 31 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT01329900 2020-07-08

Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas

50 enrolled 7 charts

Lymphoma

NCT01578707 2019-12-18

RESONATE™

Phase 3 Completed

391 enrolled 14 charts

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01532700 2019-09-24

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

28 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01659021 2019-08-14

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Phase 3 Terminated

261 enrolled 21 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01039376 2019-07-30

PROLONG

Phase 3 Terminated

480 enrolled 30 charts

Leukemia, B-Cell

NCT00748189 2019-06-25

COMPLEMENT 1

Phase 3 Terminated

447 enrolled 32 charts

Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01002755 2019-05-07

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Classical hematologyLymphoidOther hematologic neoplasm

36 enrolled 7 charts

Lymphadenopathy, Agammaglobulinemia, Fatigue, Fever, Lymphocytosis, Paraproteinemias, Thrombocytopenia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01024010 2018-09-18

Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

82 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01294579 2018-08-09

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

49 enrolled 13 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT02419469 2018-06-11

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

1 enrolled 4 charts

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01191190 2018-05-08

CRC027

21 enrolled 12 charts

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01626352 2017-11-22

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

22 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT01848145 2017-06-06

Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia

34 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00811733 2017-05-30

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

37 enrolled 25 charts

Waldenstrom Macroglobulinemia

NCT01077622 2017-05-30

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

10 enrolled 35 charts

Leukemia, B-Cell

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

99 enrolled 27 charts

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01113632 2016-09-20

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

77 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01536067 2016-06-10

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

3 enrolled 4 charts

Waldenstrom Macroglobulinemia

NCT01010568 2015-12-15

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

10 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01563055 2015-08-10

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

10 enrolled 52 charts

Leukemia, B-Cell

NCT00622388 2015-07-24

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

81 enrolled 18 charts

Lymphoma, Large B-Cell, Diffuse

NCT01217749 2015-06-25

PCYC-1109-CA

Phase 1/2 Completed

71 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01397591 2014-07-30

Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

3 enrolled 6 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00494780 2014-07-11

MUNIN

59 enrolled 21 charts

Lymphoma, Follicular

NCT00349349 2014-06-04

HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

223 enrolled 31 charts

Leukemia, B-Cell

NCT00802737 2014-05-14

Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)

Phase 4 Completed

29 enrolled 18 charts

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00410163 2014-02-10

BIFROST

61 enrolled 22 charts

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00823719 2013-03-12

Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

61 enrolled 25 charts

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01108341 2012-08-28

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

50 enrolled 10 charts